Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Real-time RT-PCR assays for discriminating influenza B virus Yamagata and Victoria lineages

Mina Nakauchi,a Ikuyo Takayama,b Hitoshi Takahashi,a Kunihiro Oba,b Hideyuki Kubo,c Atsushi Kaida,c Masato Tashiroa, Tsutomu Kageyama,a,*

aInfluenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan
bDepartment of Pediatrics, Showa General Hospital, 8-1-1, Hanakoganei, Kodaira, Tokyo 187-8510, Japan
cDepartment of Microbiology, Osaka City Institute of Public Health and Environmental Sciences, 8-34 Tojo-cho, Tennoji-ku, Osaka 543-0026, Japan

A B S T R A C T

Since the late 1980s, two genetically and antigenically distinct lineages of influenza B virus, namely, B/Victoria/2/87-like (B/Victoria) and B/Yamagata/16/88-like (B/Yamagata), have co-circulated. In this study, one-step real-time reverse transcription-PCR (rRT-PCR) assays were developed to differentiate B/Victoria and B/Yamagata lineages. The assays were evaluated using in vitro transcribed control RNA isolated viruses, and other respiratory pathogenic viruses, and were shown to have high sensitivity, good linearity ($R^2 = 0.99$), and high specificity. Using the developed rRT-PCR assays, 169 clinical specimens collected between 2010 and 2013 were then tested, resulting in the identification of 20 clinical specimens as positive for influenza B virus. Of these, 14 and 6 samples were identified as positive for the B/Victoria and B/Yamagata lineages, respectively, whereas 149 samples were negative for the influenza B virus. The rRT-PCR assays were also examined using 20 clinical isolates from 20 influenza B virus-positive specimens, revealing that there was no discrepancy between the results from the rRT-PCR assays and the hemagglutination inhibition (HI) test, with the exception that one clinical isolate with different antigenicity could not be discriminated by the HI test. The present results suggest that these highly sensitive and specific assays are useful not only for diagnosing influenza viruses but also for their surveillance.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Influenza A, B, and C viruses are members of the Orthomyxoviridae family of RNA viruses, circulate in humans, and cause respiratory illness every year (Wright et al., 2007). Influenza A viruses comprise a number of subtypes, whereas influenza B and C viruses are not divided into subtypes (Wright et al., 2007). Since the late 1980s, two genetically and antigenically distinct lineages of influenza B virus, namely, B/Victoria/2/87-like (B/Victoria lineage) and B/Yamagata/16/88-like (B/Yamagata lineage), have co-circulated (Kanegae et al., 1990; Rota et al., 1990). In Japan, the majority of circulating influenza B viruses during the 2010/2011 influenza season was of the B/Victoria lineage. During the 2011/2012 and 2012/2013 seasons, both lineages co-circulated; the B/Victoria lineage was dominant in the 2011/2012 season, whereas the B/Yamagata lineage was dominant in the 2012/2013 season (http://www.who.int/influenza/gisrs_laboratory/flunet/en/). The trivalent vaccines currently licensed for use in Japan include only one lineage of the influenza B virus; therefore, it is important to conduct surveillance to know which lineage is predominant at any one time to select a candidate virus for the generation of vaccines.

Conventionally, the two lineages of the influenza B virus are differentiated antigenically by the hemagglutination inhibition (HI) test with immune sera raised against each lineage. The HI test is a conventional method to define the type, subtype, and lineage of clinical isolates; however, it is a time-consuming and complicated process that includes the isolation of viruses from clinical specimens and the preparation of immune sera. Recently, PCR-based assays for the rapid diagnosis of influenza viruses have become the gold standard and many real-time RT-PCR (rRT-PCR) assays have been reported (Wang and Taubenberger, 2010). Compared with the HI test, rRT-PCR assays have the advantage of being able to be performed rapidly, sensitively, and specifically using purified RNA from clinical specimens without requiring a viral isolation step.

In Japan, several rRT-PCR assays for typing influenza A and B viruses and subtyping influenza A viruses were developed using minor groove binder (MGB) probes; the assay scheme was established and shared with 74 prefectural and municipal public health
institutes for the diagnosis and surveillance of influenza viruses (Nakauchi et al., 2011b). However, rRT-PCR assay for universally detecting influenza B viruses, whose target region was the non-structural protein (NS) gene (B/NS rRT-PCR; the sequences of the primers and probe are listed in Table 1), was not able to discriminate between the B/Victoria and B/Yamagata lineages.

An rRT-PCR assay for discriminating the B/Victoria and B/Yamagata lineages was first reported by Biere et al. (2010). However, the sequences of the forward primer and the two probes used in the study of Biere et al. had low homology with the recent influenza B viruses circulating in Japan. Another rRT-PCR assay for discriminating these two lineages was reported by Zhang et al. (2012); however, this method did not use MGB probes, resulting in different conditions for this assay compared to the assay used in Japan.

To monitor rapidly and simply the circulating situation of these two lineages of influenza B virus and as a complement to the HI test, rRT-PCR assays for discriminating the B/Victoria and B/Yamagata lineages (B/Vic rRT-PCR and B/Yam rRT-PCR, respectively) were developed by using MGB probes in this study. The highly sensitive and specific rRT-PCR assays for detecting and discriminating these two lineages of influenza B virus will be useful for the diagnosis and surveillance of influenza B viruses.

2. Materials and methods

2.1. Primer and probe design

The nucleotide sequences of the hemagglutinin (HA) gene from influenza B viruses posted over the past 5 years in the Global Initiative on Sharing Avian Influenza Data (GISAID) database were aligned using ClustalW software (Larkin et al., 2007). On the basis of the sequences of the HA gene, 2 probes were designed to discriminate between the B/Victoria and B/Yamagata lineages in which 6 nucleotides (nt) out of the 18 nt probe sequence were different between these lineages. The sequences and positions of the primers and probes are listed in Table 1.

2.2. Viruses

All influenza viruses included in this study were isolated using Madin–Darby Canine Kidney (MDCK) cells. In addition to B/Florida/4/2006 (B/Yamagata), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata), several influenza A viruses were used to validate the specificity of the assays: A/Uruguay/716/2007 (H3N2), A/Perth/10/2009 (H3N2), A/Narita/1/2009 (H1N1)pdm09, and A/California/07/2009 (H1N1)pdm09.

The following the viral respiratory pathogens (the clinical isolates) were used to validate the specificity of the assays: respiratory syncytial virus A and B; human parainfluenza virus types 1–4; human rhinovirus types A and B; human metapneumovirus types A1 and B2; human coronaviruses OC43, 229E, HKU1, and NL63; human bocavirus; human enterovirus; and human adenoviruses 2 and 4.

2.3. Preparation of RNA transcript controls

To construct an RNA-positive control for the B/NS, B/Vic, and B/Yam rRT-PCR assays, each target gene segment (described in Table 2) was amplified by RT-PCR, and the resulting PCR product, containing the T7 promoter, was then transcribed in vitro. The procedure is described in detailed below.

The primer Uni5 (5′-CCAGAACG-3′) (Zou, 1997) was used for RT using a SuperScript® III Reverse Transcriptase Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. The NS gene segment of B/Florida/4/2006 was amplified using the following primer pair: TypeB-NS-F (–22–6) (5′-TAGTACAGGGGAAACAGGCTGGC-3′) and TypeB-NS-R (+1–29) + T7 (5′-TAATCAGCTACATATGGGTAGTAAACAGG-ATTTTATTTAAT-3′). The HA gene segments of B/Brunei/
60/2008 (B/Victoria lineage) and B/Massachusetts/2/2012 (B/Yamagata lineage) viruses were amplified using the following primer pairs: FLUB Vic HA-F (5'-ATGAGGCAATATTGACTAC-TCTAGTCTAGACATCC-3') and FLUB HA-R T7 (5'-TAATAGCAGTCTACATTTAGCTTAAAGCAGATGACACAA-3'), and FLUB Yam HA-F (5'-ATGAGGCAATATTGACTACTAATGGTACATACACATCC-3'), and FLUB HA-R T7, respectively. PCR was performed using Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific). The PCR product was gel purified using a QiAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and transcribed using the T7 Ribomax™ Express Large Scale RNA Production System (Promega, Madison, WI) according to the manufacturer's instructions. After TURBO® DNase (Thermo Fisher Scientific) digestion to remove the residues of the RT-PCR products, the transcribed RNA was purified twice using the TRIzol Reagent (Fisher Scientific), and then the dNTPs and NTPs were removed using MicroSpin G-50 Columns (GE Healthcare, Piscataway, NJ) according to the manufacturer's instructions. The purified transcribed RNA was quantified by spectrophotometric analysis and its integrity was assessed with a 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA). Total RNA was prepared as described in Section 2.6.

2.4. Sequencing of the partial HA gene of a clinical isolate

To confirm the lineages of a clinical isolate, the HA1 region of the HA gene of B/Tokyo/F1-015/2011 was sequenced. To amplify the HA1 region, using extracted RNA, RT and PCR were carried out as described in Section 2.3 with the paired primers BHA1-N and BHA1-C (listed in Table 1) for PCR. The PCR products were purified and then sequenced using 6 primers (listed in Table 1). Total RNA was prepared as described in Section 2.6.

2.5. Clinical specimens

Nasal and/or pharyngeal swabs collected from patients with influenza-like illness and suspended in a UTG 360C Kit (Copen, Brescia, Italy) were obtained from Showa General Hospital, Japan. These specimens were collected between 2010 and 2013. The study protocol was approved by the Ethics Committee at NID, and the study was performed in compliance with the Declaration of Helsinki. Informed consent was obtained from all patients.

2.6. RNA preparation

Supernatants from cultured MDCK cells were centrifuged at 10,000 × g for 10 min. Viral RNA was prepared from 140 μL of the supernatant using a QiAamp® Viral RNA Kit (Qiagen) according to the manufacturer's instructions with the slight modification that the viral RNA was eluted in 70 μL AVE buffer (Qiagen).

Total RNA was prepared from the clinical specimens using a QiAamp® Viral RNA Kit (Qiagen) (using 140 μL of clinical specimen) or MagMAX™ 96 Viral Isolation Kit (Thermo Fisher Scientific) (using 50 μL of clinical specimen) with KingFisher Flex (Thermo Fisher Scientific) according to the manufacturers' instructions. Total RNA from the 140-μL clinical specimens was eluted with 60 μL AVE buffer (Qiagen), whereas total RNA from the 50-μL clinical specimens was eluted with 30 μL elution buffer (Thermo Fisher Scientific).

2.7. One-step rRT-PCR assay

The reaction was performed using a Quantitect® Probe RT-PCR Kit (Qiagen) according to the manufacturer's instructions. Briefly, the 25 μL assay contained 12.5 μL of 2 × Quantitect Probe PCR Master Mix, 0.25 μL Quantitector RT Mix, 0.1 μL RNase Inhibitor (Thermo Fisher Scientific), 1.5 μL of 10 μM forward primer, 1.5 μL of 10 μM reverse primer, 0.5 μL of 5 μM probe, 3.65 μL distilled water, and 5 μL RNA template. Cycling was performed as follows: 30 min at 50°C to activate RT, followed by an initial denaturation step for 15 min at 95°C and 45 cycles of amplification (denaturation at 95°C for 15s and annealing as well as extension at 56°C for 75s) using a LightCycler® 480 (Roche Molecular Biochemicals, Basel, Switzerland). Fluorescent signals were collected during the annealing and extension steps, and the amplification data were analyzed using LightCycler® 480 SW1.5 software according to the manufacturer's instructions. The r-Taq PCR assays for typing influenza A and B viruses and subtyping H1 pdm and H3 (Nakauchi et al., 2011b) were also performed for the diagnosis of the clinical specimens.

2.8. One-step duplex rRT-PCR assay

The reaction was performed using a Quantitect® Virus + ROX Vial Kit (Qiagen) according to the manufacturer's instructions and as described previously (Nakauchi et al., 2011a). For testing the clinical isolates using cultured medium, the 20 μL assay contained 4 μL of 5× Quantitect Virus NR Master Mix, 0.2 μL Quantitect Virus RT Mix, 1.2 μL each of two 10 μM forward primers, 1.2 μL each of two 10 μM reverse primers, 0.4 μL each of two 5 μM probes, 7.6 or 8 μL distilled water, and 2 μL culture medium. For testing the clinical specimens using extracted RNA, 5 μL of RNA template were used. Cycling was performed as follows: 20 min at 50°C to activate RT, followed by an initial denaturation step for 5 min at 95°C and 45 cycles of amplification (denaturation at 95°C for 15s and annealing as well as extension at 56°C for 45s) using a LightCycler® 480 (Roche Molecular Biochemicals). Fluorescent signals were collected during the annealing and extension steps, and the amplification and endpoint data were analyzed using LightCycler® 480 SW1.5 software according to the manufacturer's instructions.

2.9. HI test

Ferret antisera raised against MDCK-grown B/Brisbane/60/2008 (B/Victoria lineage) and B/Massachusetts/2/2012 (B/Yamagata lineage) viruses were tested with RDEII (Denka Seiken Co., Tokyo, Japan) to remove nonspecific inhibitors. A 1:10 dilution of the treated sera was prepared with phosphate-buffered saline. Two-fold serial dilutions of sera were mixed with 4 HA units of antigen virus per well and preincubated for 60 min in 96-well plates at room temperature; 0.5% turkey red blood cells were added, and the plate was incubated for 45 min at room temperature. HI titers of the sera were determined as the highest dilution that did not display hemagglutinating activity (http://apps.who.int/iris/bitstream/10665/44518/1/9789241548090_eng.pdf:1-153).

3. Results

3.1. Development of the rRT-PCR assays

The specificity of the B/NS rRT-PCR assay for detecting both lineages of influenza B virus, and the B/Vic and B/Yam rRT-PCR assays for discriminating the two lineages of influenza B virus were evaluated using B/Victoria, B/Yamagata, A/H3N2, and A/H1N1 pdm influenza viruses and other viral respiratory pathogens. The B/NS rRT-PCR assay reacted specifically with both lineages of influenza B virus (data not shown). The B/Vic rRT-PCR assay reacted specifically with B/Victoria, but not with B/Yamagata, whereas the B/Yam rRT-PCR assay reacted specifically with B/Yamagata, but not with B/Victoria (data not shown). All three assays showed no cross-reactivity against influenza A viruses or other viral respiratory pathogens (data not shown).

The detection limit of each assay was determined by performing serial dilutions of in vitro transcribed control viral RNA for 6
replicates in each assay. The detection limits of the B/NS, B/Vic, and B/Yam rRT-PCR assays were determined to be 8.27, 4.31, and 3.85 copies/reaction, respectively, calculated by a Probit analysis using the results shown in Table 2. A standard curve of each assay was also generated (Fig. 1). The standard curve showed a linear relationship between the log of the viral titer and the crossing point (Cp) value for all assays (Fig. 1). The correlation coefficient of the standard curve was 0.99 for all assays, indicating a precise log–linear relationship between the viral titer and Cp value (Fig. 1).

3.2. Validation of the rRT-PCR assays using clinical specimens

From 2010 to 2013, clinical specimens (nasal and/or pharyngeal swabs) from patients with an influenza-like illness (n = 169) were obtained, and the B/NS rRT-PCR assay was performed on these samples. As a result, 20 out of 149 samples were identified as positive for influenza B virus. Twenty B/NS-positive samples were then tested using the B/Vic and B/Yam rRT-PCR assays, revealing that 14 and 6 samples were identified as positive for the B/Victoria and B/Yamagata lineages, respectively.

3.3. Validation of the rRT-PCR assays using clinical isolates

Clinical isolates from 20 influenza B virus-positive clinical specimens (listed in Table 3) were tested using the B/NS, B/Vic, and B/Yam rRT-PCR assays and also by the conventionally performed HI test. As shown in Table 3, 14 and 6 clinical isolates were identified as positive for the B/Victoria and B/Yamagata lineages, respectively, consistent with the results of the three rRT-PCR assays on the original clinical specimens. Antiserum against B/Massachusetts/2/2012 (B/Yamagata) reacted with all 6 B/Yam-positive clinical isolates. Antiserum against B/Brisbane/60/2008 (B/Victoria) reacted with 13 B/Vic-positive clinical isolates; however, it reacted poorly with one B/Vic-positive clinical isolate, B/Tokyo/F11-015/2011, with 8-fold-reduced HI titers from the homologous titer. To identify the cause of the low reaction of the antiserum against B/Brisbane/60/2008 with B/Tokyo/F11-015/2011, the HA1 region (1–341 amino acids) of the HA gene was sequenced and compared with the HA1 region of B/Brisbane/60/2008. This revealed that B/Tokyo/F11-015/2011 has 8 amino acid mutations (N26D, T52I, K90N, 1161V, K180N, K182R, P187S, and A217T).

4. Discussion

The B/NS rRT-PCR assay used for detecting influenza B viruses and the B/Vic and B/Yam rRT-PCR assays used for discriminating the two lineages of the influenza B virus, were shown to have good linearity ($R^2 = 0.99$) and high sensitivity (Table 2 and Fig. 1). No cross-reactivity or nonspecific reactions were observed in any of the assays performed using isolated viruses and clinical specimens (data not shown). In the assay performed using clinical specimens, 20 samples were identified as positive for influenza B virus and 149 samples were negative in the B/NS rRT-PCR assay. Of the 149 B/NS-negative samples, 81 and 3 samples were identified as positive for A/H3 and A/H1 pdm by performing the previously developed Type A, H1 pdm, and H3 rRT-PCR assays (Nakauchi et al., 2011b), and no influenza A or B viruses were detected in the remaining 65 samples. All 20 B/NS-positive clinical samples were discriminated either as B/Victoria or B/Yamagata by the B/Vic and B/Yam rRT-PCR assays, respectively. These results suggest that these three rRT-PCR assays are highly sensitive and specific for each target gene and should thus be of great use for detecting and discriminating the two lineages of the influenza B virus.
Table 3
Comparing the HI test and rRT-PCR assays using clinical isolates.

| Influenza B virus     | HI titer* of postinfection ferret antisera | rRT-PCR** |
|-----------------------|-------------------------------------------|-----------|
|                       | B/Brisbane/60/2008                        | B/Massachusetts/2/2012 | B/NS | B/Vic | B/Yam |
| Reference virus       |                                           |           |       |       |       |
| B/Brisbane/60/2008    | 80                                        | <10       | +     | +     | −     |
| B/Massachusetts/2/2012| <10                                       | 160       | +     | −     | +     |
| Clinical isolate (test virus) |                                           |           |       |       |       |
| B/Tokyo/Sh/F1-015/2011| 10                                        | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-026/2011| 40                                        | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-030/2011| 80                                        | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-031/2011| 80                                        | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-032/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-068/2011| 160                                       | 10        | +     | +     | −     |
| B/Tokyo/Sh/F1-082/2011| 160                                       | 160       | +     | +     | −     |
| B/Tokyo/Sh/F1-099/2011| 160                                       | <10       | +     | +     | +     |
| B/Tokyo/Sh/F1-103/2011| 10                                        | 160       | +     | +     | +     |
| B/Tokyo/Sh/F1-138/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-143/2011| 10                                        | 160       | +     | +     | −     |
| B/Tokyo/Sh/F1-155/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-157/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-159/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-161/2011| <10                                       | 160       | +     | +     | −     |
| B/Tokyo/Sh/F1-165/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-170/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-173/2011| 160                                       | <10       | +     | +     | −     |
| B/Tokyo/Sh/F1-066/2013| 10                                        | 160       | +     | +     | +     |
| B/Tokyo/Sh/F1-068/2013| 10                                        | 160       | +     | +     | +     |

* The underlined titer indicates the homologous titers of the antiserum.

** + “+” and “−” indicate “positive” and “negative” for each rRT-PCR assay.

The results of the HI test and the B/Vic and B/Yam rRT-PCR assays were compared using 20 clinical isolates (Table 3) from 20 influenza B virus-positive clinical samples. The results of rRT-PCR assays corresponded to those of the HI test with one exception. B/Tokyo/F11-015/2011 and its original specimen were identified as positive for the B/Vic and B/Yam rRT-PCR assays; however, antiserum against B/Brisbane/60/2008 reacted poorly with B/Tokyo/F11-015/2011. It was found that B/Tokyo/F11-015/2011 has eight different amino acids, namely, N26D, T52I, K90N, 1161V, K180N, K182R, P187S, and A217T, in the HA1 region when compared with B/Brisbane/60/2008. The amino acid positions at 182 and 217, where B/Tokyo/F11-015/2011 has mutations, were reported as antigenic sites by analyzing escape mutants from monoclonal antibodies (Tung et al., 2004), and the Thr to Ile mutation at position 52 is also known to affect antigenicity (unpublished data from the Influenza Surveillance Group of Japan). Considering these data, B/Tokyo/F11-015/2011 is antigenically different from B/Brisbane/60/2008; thus, the HI test could not identify B/Tokyo/F11-015/2011 as B/Victoria.

The HI test has been performed conventionally for determining type, subtype, and lineage of influenza viruses and for detecting antigenic differences between reference and test viruses. The HI test is a very useful method for monitoring the antigenicity of circulating influenza viruses in humans to select a virus for vaccine production; however, the HI test is not able to detect influenza viruses when the test virus is antigenically different from the reference virus. The combination of the B/NS, B/Vic, and B/Yam rRT-PCR assays developed in this study was able to detect and discriminate both lineages of the influenza B virus, including a virus that was undetected by the HI test, with high sensitivity and specificity (Table 3); however, the rRT-PCR assays cannot be used to compare antigenic differences. Therefore, it is important to use the rRT-PCR assays in cooperation with the HI test for conducting surveillance of influenza B viruses.

To facilitate the assay scheme of the B/Vic and B/Yam rRT-PCR assays, a duplex rRT-PCR assay for discriminating the two lineages of the influenza B virus was also constructed. No discrepancy was found between the results from the duplex rRT-PCR assay and the B/Vic and B/Yam rRT-PCR assays for 20 clinical specimens and 20 clinical isolates (Table 3 and Fig. 2). It is noteworthy that the duplex assay could be performed using clinical isolates without an RNA purification step, since a sufficient amount of viral RNA may be released from the virion under the RT conditions (50 °C, 20 min). When considering the handling of a large number of clinical isolates, this assay can be performed rapidly and simply with a lower risk of cross-contamination because an RNA purification step is unnecessary.

In conclusion, the highly sensitive and specific B/NS, B/Vic, and B/Yam rRT-PCR assays developed in this study will be very useful not only for laboratory diagnostic tests but also for speeding up surveillance by discriminating the lineages of influenza B viruses in clinical specimens. Considering that the trivalent vaccines currently licensed for use in Japan include only one lineage of the influenza B virus, the assays are also powerful tools for the rapid recognition of the predominant lineage of influenza B virus at any one time and helpful to decide which candidate virus should be included in vaccines.

Acknowledgment

We appreciate Drs. Noriko Kishida, Hong Xu, and Takato Odagiri, Influenza Virus Research Center, National Institute of Infectious Diseases for providing ferret antisera and for helpful advice to interpret the results of the HI test.

References

Biere, B., Bauer, B., Schweiger, B., 2010. Differentiation of influenza B virus lineages Yamagata and Victoria by real-time PCR. J. Clin. Microbiol. 48, 1425–1427.

Canegae, Y., Sugita, S., Endo, A., Ishida, M., Senya, S., Osako, K., Nerome, K., Oya, A., 1990. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J. Virol. 64, 2860–2865.

Larkin, M.A., Blackshields, G., Brown, N.P., Chenia, R., McGettigan, P.A., McWilliam, H., Valentin, F., Wallace, I.M., Wil, A., Lopez, R., Thompson, J.D., Gibson, T.J.,
Higgins, D.G., 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948.
Nakauchi, M., Ujike, M., Obuchi, M., Takashita, E., Takayama, I., Ejima, M., Oba, K., Konomi, N., Odagiri, T., Tashiro, M., Kageyama, T., 2011a. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. J. Med. Virol. 83, 1121–1127.
Nakauchi, M., Yasui, Y., Miyoshi, T., Minagawa, H., Tanaka, T., Tashiro, M., Kageyama, T., 2011b. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J. Virol. Methods 171, 156–162.
Rota, P.A., Wallis, T.R., Harmon, M.W., Rota, J.S., Kendal, A.P., Nerome, K., 1990. Circulation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175, 59–68.
Tung, C.S., Goodman, J.L., Lu, H., Macken, C.A., 2004. Homology model of the structure of influenza B virus HA1. J. Gen. Virol. 85, 3249–3259.
Wang, R., Taubenberger, J.K., 2010. Methods for molecular surveillance of influenza. Expert Rev. Anti-Infect. Ther. 8, 517–527.
Wright, P.F., Neumann, G., Kawaoka, Y., 2007. Orthomyxoviruses. In: Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., Straus, S.E. (Eds.), Fields Virology, fifth ed. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 1691–1740.
Zhang, N., Fang, S., Wang, T., Li, J., Cheng, X., Zhao, C., Wang, X., Lv, X., Wu, C., Zhang, R., Cheng, J., Xue, H., Lu, Z., 2012. Applicability of a sensitive duplex real-time PCR assay for identifying B/Yamagata and B/Victoria lineages of influenza virus from clinical specimens. Appl. Microbiol. Biotechnol. 93, 797–805.
Zou, S., 1997. A practical approach to genetic screening for influenza virus variants. J. Clin. Microbiol. 35, 2623–2627.